ONC
BeOne Medicines Ltd. American Depositary Shares
About: Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
Employees: 11,000
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
158% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 26
50% more funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 9 (+3) [Q1 2025]
43% more capital invested
Capital invested by funds: $8.06B [Q4 2024] → $11.6B (+$3.5B) [Q1 2025]
16% more funds holding
Funds holding: 223 [Q4 2024] → 259 (+36) [Q1 2025]
9% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 75
3% more call options, than puts
Call options by funds: $44.1M | Put options by funds: $42.9M
0.18% less ownership
Funds ownership: 3.49% [Q4 2024] → 3.31% (-0.18%) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$311
15%
upside
Avg. target
$325
20%
upside
High target
$350
30%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
RBC Capital Gregory Renza | 15%upside $311 | Outperform Maintained | 8 May 2025 |
Guggenheim Michael Schmidt | 30%upside $350 | Buy Maintained | 8 May 2025 |
TD Securities Yaron Werber | 24%upside $334 | Buy Reiterated | 24 Apr 2025 |
JP Morgan Jessica Fye | 18%upside $317 | Overweight Maintained | 21 Apr 2025 |
RBC Capital Greg Renza | 16%upside $312 | Outperform Initiated | 7 Apr 2025 |
Financial journalist opinion
Based on 10 articles about ONC published over the past 30 days
Neutral
Business Wire
3 days ago
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association (EHA) Congress. Four oral presentations highlight the promising clinical activity of BeOne's next-generation BCL2 inhibitor sonrotoclax, BTK protein degrader BGB-16673, and the backbone of our hematology franchise, BTK inhibitor BRUKINSA (zanubrutinib), which ha.
Neutral
Business Wire
3 days ago
U.S. FDA Approves Tablet Formulation of BeOne's BRUKINSA® for All Approved Indications
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of BRUKINSA® (zanubrutinib) for all five approved indications. BRUKINSA remains the leader in new chronic lymphocytic leukemia (CLL) patient starts across all lines of therapy in the U.S., and for the first time, has become the overall BTK inhibitor market share leader.
Neutral
Business Wire
4 days ago
BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that it will host an Investor R&D Day in New York City and via webcast on June 26, 2025 at 8:30 am ET. John V. Oyler, Co-Founder, Chairman, and CEO of BeOne, along with the Company's leadership team and distinguished key opinion leaders, will provide an update on BeOne's extensive global innovation pipeline and platforms, including new assets, targets.
Positive
Investors Business Daily
1 week ago
Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple
Cancer stock BeiGene renamed itself as BeOne. Shares have gained 40% year to date, outperforming the S&P 500.
Positive
Seeking Alpha
1 week ago
BeOne Medicines: Competitive Advantage Of Zanubrutinib In The CLL Field
Zanubrutinib is currently best-in-class among BTK inhibitors for CLL, with superior efficacy and safety over ibrutinib and strong market momentum. Zanubrutinib will be in the leading position in CLL in the next 5 years, given the best-in-class BTK inhibitor and potential best combined regimen of zanubrutinib plus sonrotoclax in 2027. Pirtobrutinib maybe a powerful competitor to zanubrutinib when the phase 3 BRUIN CLL-314 trial PFS data is available in 2027.
Neutral
Business Wire
1 week ago
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, includi.
Neutral
Business Wire
2 weeks ago
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA's Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (A.
Neutral
Business Wire
2 weeks ago
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
SAN CARLOS, Calif. & BASEL, Switzerland--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company formerly known as BeiGene, Ltd., today announced its new name and redomiciliation to Switzerland are officially in effect, marking a significant milestone in the Company's evolution. “BeOne represents more than a name change—it's not only a reflection of who we are today as a leading global oncology company, but also our ambition to redefine what's po.
Neutral
Business Wire
2 weeks ago
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with recurrent, not amenable to curative surger.
Neutral
Business Wire
3 weeks ago
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share 23 abstracts featuring new data across its hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, May 30 – June 3, 2025. With two abstracts selected for rapid oral presentation, these data reflect the Company's vision to address cancer.
Charts implemented using Lightweight Charts™